The Food and Drug Administration authorized two oral antiviral treatments for COVID-19 this week, giving doctors the first pill-based therapies designed for high-risk patients to take at home during the earliest days of infection as the rapidly spreading Omicron variant drives a new surge in cases.

On Wednesday, the FDA authorized Pfizer’s Paxlovid for adults and pediatric patients age 12 and older who weigh at least 40 kilograms, have mild-to-moderate COVID-19 and face high risk of progressing to severe disease. On Thursday, the agency separately authorized Merck and Ridgeback’s molnupiravir for certain high-risk adults when other authorized treatment options are not accessible or clinically appropriate.

Paxlovid arrives with strong trial results

Paxlovid combines Pfizer’s antiviral nirmatrelvir with ritonavir, a medicine used to slow the breakdown of the active drug and keep effective concentrations in the body longer. Treatment must begin as soon as possible after diagnosis and within five days of symptom onset, making rapid testing and prescribing essential to its effectiveness in routine care.

Pfizer said in its authorization announcement that the emergency-use decision followed a randomized trial in high-risk, non-hospitalized adults. The company’s final Phase 2/3 analysis reported an 88% reduction in the risk of hospitalization or death compared with placebo when treatment was started within five days of symptoms, with no deaths in the treatment group during the reported analysis.

The result has made Paxlovid one of the most closely watched tools in the pandemic response. Unlike monoclonal antibodies, which generally require infusion or injection in a clinical setting, an oral course can be dispensed for home use. That could reduce logistical barriers if supplies become adequate and patients can obtain testing and prescriptions quickly enough.

Molnupiravir adds an option with narrower use

Molnupiravir works through a different mechanism, introducing errors as the virus copies its genetic material. The FDA limited its authorization to adults because the drug may affect bone and cartilage growth and is not authorized for patients under 18. The agency also said it is not recommended for use during pregnancy and emphasized that it should be used when alternative authorized treatments are unavailable or inappropriate.

Merck and Ridgeback said in their December 23 announcement that the drug is intended for adults with mild-to-moderate disease who are at high risk for severe outcomes. Earlier final trial data showed a smaller reduction in hospitalization or death than initially reported in an interim analysis, one reason regulators and advisers have treated the drug as an additional option rather than the preferred oral therapy.

The underlying Phase 3 evidence was published this month, and Merck highlighted the peer-reviewed results in a December 16 release. The authorization nevertheless expands the treatment arsenal at a moment when some monoclonal antibodies may have reduced activity against Omicron.

The five-day treatment window creates a systems challenge

Both pills are most useful only if patients move quickly from symptoms to testing, diagnosis, prescribing and pharmacy access. That requirement exposes weaknesses in a health system where testing can be delayed, primary-care access is uneven and holiday demand is already straining pharmacies and laboratories.

A Washington Post report on Paxlovid’s authorization noted both the promise of a highly effective oral treatment and the initial constraint of limited supply. Manufacturing a complex antiviral regimen at global scale will take time, meaning authorization does not immediately translate into universal availability.

Molnupiravir will also be distributed under federal purchasing agreements, but its narrower authorization and reproductive cautions mean clinicians must weigh eligibility carefully. A CBS News report on Thursday’s decision described the drug as a second oral option while emphasizing the FDA’s preference for other treatments when they can be used.

Antivirals complement vaccines rather than replace them

Federal officials continue to stress that treatment is not a substitute for vaccination. Vaccines and boosters aim to prevent severe disease before infection progresses, while antivirals intervene after a person is already infected. The public-health value of the pills lies in adding a second line of defense for people who become ill, especially those with age or medical conditions that raise their risk.

Omicron increases the urgency. Cases are rising quickly in multiple parts of the country, and the variant’s mutations have raised concern about reduced effectiveness for some antibody therapies. Small-molecule antivirals target stages of viral replication that are less dependent on the spike protein, giving officials reason to expect continued activity, though real-world performance against Omicron will require continued observation.

The consecutive authorizations mark an important shift in the treatment landscape. For much of the pandemic, outpatient therapy has depended on infusions, injections and limited clinical capacity. The United States now has two authorized antiviral pills that can be taken at home. Their impact will depend not only on how well they work biologically, but on whether patients can be diagnosed and treated within a narrow window—and whether manufacturers can produce enough courses for a winter wave that is accelerating rapidly.